Core Viewpoint - Sinopharm Group is a leading player in the pharmaceutical distribution and healthcare sector in China, focusing on expanding its market presence and enhancing operational efficiency [1] Group 1: Company Overview - Sinopharm Group is recognized as a major pharmaceutical distributor in China, with a comprehensive network that supports its extensive product offerings [1] - The company is involved in various segments of the healthcare industry, including drug distribution, retail pharmacy, and healthcare services [1] Group 2: Market Position - Sinopharm Group holds a significant market share in the pharmaceutical distribution sector, benefiting from the growing demand for healthcare products in China [1] - The company is strategically positioned to capitalize on the increasing healthcare expenditure and the expansion of the healthcare infrastructure in the country [1]

Core Insights - The conference focused on how AI can reshape the value growth curve of Hong Kong-listed companies, emphasizing the importance of innovation and collaboration in driving business growth through technology [1] Group 1: AI Empowering R&D Innovation - AI technology is significantly enhancing R&D efficiency and operational effectiveness in traditional industries, particularly in cancer screening and vaccine development [2][4] - Companies like MiRui are transitioning from traditional statistical models to AI-driven gene diagnosis, which is expected to improve cancer early screening accuracy as data accumulates [1][2] - The integration of AI in R&D processes allows for efficient molecular sequence design and analysis, accelerating the development of innovative vaccines [2][4] Group 2: Optimizing Business Operations - AI is being utilized to enhance operational efficiency in various sectors, including logistics and patient management, leading to improved customer experiences [3][4] - National Pharmaceutical Holdings has implemented AI in its extensive drug distribution network, optimizing inventory management and compliance with healthcare regulations [3] - MiRui's AI platform facilitates training and data interpretation, enhancing communication with clients and healthcare professionals [3] Group 3: Sustainable AI Drive - Companies are recognizing the need to convert AI's potential into sustainable core drivers for their operations, aligning AI technology with strategic development plans [5] - The industry is moving towards a state where AI applications become commonplace and integral to business processes, enhancing competitiveness [5] - Collaboration with leading AI firms is seen as essential for deepening AI integration within industry verticals [5]

国药控股(01099)发布公告，由于工作安排原因，孙京林先生已于2025年11月6日向董事会提出辞任执行 董事及董事会战略与投资委员会委员职务，上述辞任即时生效。于同日，董事会决议建议委任杨秉华先 生为执行董事。 ...

Core Viewpoint - China National Pharmaceutical Group (国药控股) announced the resignation of Mr. Sun Jinglin as an executive director and member of the board's strategy and investment committee, effective immediately, and proposed the appointment of Mr. Yang Binghua as the new executive director [1] Group 1 - Mr. Sun Jinglin submitted his resignation on November 6, 2025, due to work arrangement reasons [1] - The board has resolved to recommend the appointment of Mr. Yang Binghua as the executive director [1]

致：香港交易及結算所有限公司 公司名稱: 國藥控股股份有限公司 呈交日期: 2025年11月6日 I. 法定/註冊股本變動 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01099 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,341,810,740 | RMB | | 1 | RMB | | 1,341,810,740 | | 增加 / 減少 (-) | | | | | | | RMB | | | | 本月底結存 | | | 1,341,810,740 | RMB | | 1 | RMB | | 1,341,810,740 | 截至月份: 2025年10月31日 狀態: 新提交 | 2. 股份 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致之任何損 失承擔任何責任。 趙炳祥（董事長） 陳啟宇 祖敬 邢永剛 陳玉卿 文德鏞 （於中華人民共和國註冊成立之股份有限公司， 在香港以國控股份有限公司之名稱經營業務） （股份代號：01099） 董事名單與其角色和職能 國藥控股股份有限公司董事會（「董事會」）成員載列如下： 非執行董事 俞衛鋒 石晟昊 陳威如 馮蓉麗 執行董事 連萬勇（總裁） 獨立非執行董事 李培育 吳德龍 * 本公司以其中文名稱及英文名稱「 Sinopharm Group Co. Ltd. 」根據香港公司條例註冊為非香港公司。 1 董事會設立 5 個委員會。下表提供各董事會成員在這些委員會中所擔任的職位。 | 董事 | 董事會委員會 | 審核委員會 | 薪酬委員會 | 提名委員會 | 戰略與投資 委員會 | 法律合規與 環境、社會及 | | --- | --- | --- | --- | --- | --- | --- | | | | | | | | 治理委員會 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 公告 建議更换執行董事 執行董事辭任 國藥控股股份有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣佈，由於工作安 排原因，孫京林先生（「孫先生」）已於 2025 年 11月 6 日向董事會提出辭任執行董事及董事會戰略 與投資委員會（「戰略與投資委員會」）委員職務，上述辭任即時生效。 孫先生已確認其與董事會之間並無意見分歧，亦無任何與辭任有關之事宜須敬請本公司股東 （「股東」）及債權人關注。 孫先生在任職期間，恪盡職守，勤勉盡責。董事會藉此機會對其為本公司持續穩健發展及公司 治理水準不斷提升所作出的貢獻表示衷心感謝。 * 本公司以中文名稱及英文名稱「 Sinopharm Group Co. Ltd. 」根據香港公司條例註冊為非香港公司。 建議委任執行董事 於同日，董事會決議建議委任楊秉華先生（「楊先生」）為執行董事（「建議委任董事」）。 建議委任董事乃根據本公司董事提名程序，由董事會提名委員會 ...

Core Viewpoint - China National Pharmaceutical Group (Sinopharm) is enhancing its strategic cooperation with leading global pharmaceutical companies such as AstraZeneca, Bristol-Myers Squibb, Eisai China, and Gilead Sciences through productive dialogues focused on current collaboration outcomes, future strategic alignment, and innovative business models [1] Group 1 - Sinopharm is engaging in effective discussions with multiple top-tier pharmaceutical firms [1] - The dialogues aim to inject new momentum into the ongoing strategic cooperation [1] - The focus includes exploring future strategic synergies and innovative business models [1]

Core Viewpoint - China National Pharmaceutical Group (国药控股) reported a decline in revenue and net profit for China National Pharmaceutical Industry (国药一致) in the first three quarters of 2025, indicating challenges in the current market environment [1] Financial Performance - For the first three quarters of 2025, the company achieved a revenue of 55.124 billion yuan, a year-on-year decrease of 2.38% [1] - The net profit attributable to shareholders was 0.957 billion yuan, reflecting a year-on-year decline of 10.18% [1] - Basic earnings per share stood at 1.72 yuan [1] Quarterly Performance - In the third quarter of 2025, the company reported a revenue of 18.328 billion yuan, which is a year-on-year decrease of 1.89% [1] - The net profit attributable to shareholders for the third quarter was 0.291 billion yuan, down 9.58% year-on-year [1]

Core Insights - China National Pharmaceutical Group (国药控股) reported a revenue of approximately RMB 18.328 billion for Q3 2025, representing a year-on-year decrease of 1.89% [1] - The net profit for the same period was around RMB 291 million, down 9.58% year-on-year [1] - Basic earnings per share stood at RMB 0.52 [1] Financial Performance - For the first three quarters of 2025, the total revenue was approximately RMB 55.124 billion, reflecting a year-on-year decline of 2.38% [1] - The net profit for the first three quarters was about RMB 957 million, which is a decrease of 10.18% compared to the previous year [1]